Daniel Thiel
Corporate Officer/Principal at NanoSmart Pharmaceuticals, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Henry J. Smith | M | 85 |
NanoSmart Pharmaceuticals, Inc.
 NanoSmart Pharmaceuticals, Inc. BiotechnologyHealth Technology NanoSmart Pharmaceuticals, Inc. is a privately-held corporation based in Laguna Hills, CA. The private company is developing nanoparticle drug delivery platforms, including utilization of anti-nuclear antibody (ANA) to enable targeted drug delivery of existing drug therapies to areas of necrosis present in virtually all solid cancer tumors. Henry J. Smith has been the CEO of the company since 2006. | 18 years |
| Paul F. Glidden | M | - |
NanoSmart Pharmaceuticals, Inc.
NanoSmart Pharmaceuticals, Inc. BiotechnologyHealth Technology NanoSmart Pharmaceuticals, Inc. is a privately-held corporation based in Laguna Hills, CA. The private company is developing nanoparticle drug delivery platforms, including utilization of anti-nuclear antibody (ANA) to enable targeted drug delivery of existing drug therapies to areas of necrosis present in virtually all solid cancer tumors. Henry J. Smith has been the CEO of the company since 2006. | 12 years |
| James Smith | M | - |
NanoSmart Pharmaceuticals, Inc.
NanoSmart Pharmaceuticals, Inc. BiotechnologyHealth Technology NanoSmart Pharmaceuticals, Inc. is a privately-held corporation based in Laguna Hills, CA. The private company is developing nanoparticle drug delivery platforms, including utilization of anti-nuclear antibody (ANA) to enable targeted drug delivery of existing drug therapies to areas of necrosis present in virtually all solid cancer tumors. Henry J. Smith has been the CEO of the company since 2006. | - |
| Kay Metis | F | - |
NanoSmart Pharmaceuticals, Inc.
NanoSmart Pharmaceuticals, Inc. BiotechnologyHealth Technology NanoSmart Pharmaceuticals, Inc. is a privately-held corporation based in Laguna Hills, CA. The private company is developing nanoparticle drug delivery platforms, including utilization of anti-nuclear antibody (ANA) to enable targeted drug delivery of existing drug therapies to areas of necrosis present in virtually all solid cancer tumors. Henry J. Smith has been the CEO of the company since 2006. | 9 years |
Connections Chart
Multi-company connection
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 4 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Daniel Thiel
- Personal Network
